Qurient said Monday that it has presented the phase 2a clinical trial results for Q301, an atopic dermatitis treatment, at the annual American Academy of Dermatology.

Phase 2a clinical trials, conducted in the United States, showed that 30 percent of patients receiving Q301 had their symptoms improve, compared to the 4 percent from the control group. Also, the treatment had similar side effects when compared with the control group.

“With the results, the drug is attracting attention as a therapeutic agent for atopy, which can be prescribed without worrying about side effects,” the company said. “Multinational pharmaceutical companies and dermatologist have also expressed strong interest regarding the company’s phase 2b clinical trials.”

The phase 2b clinical trial will expand the drug’s target to patients who have mild symptoms and teenagers over the age of 12.

“The company is currently recruiting patients from 21 clinical centers in the U.S.,” a company official said.